3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
610
Carboplatin
375
Paclitaxel
283
Cisplatin
268
Gemcitabine
256
Pemetrexed
194
Bevacizumab
191
Nivolumab
190
Docetaxel
190
Injections
169
Cyclophosphamide
148
atezolizumab
138
Capecitabine
134
Fluorouracil
133
Oxaliplatin
132
Dexamethasone
129
Fulvestrant
115
durvalumab
114
130-nm albumin-bound paclitaxel
111
fludarabine
102
Cetuximab
101
Leucovorin
97
Rituximab
96
venetoclax
90
Lenalidomide
84
Prednisone
79
enzalutamide
78
Azacitidine
76
Irinotecan
74
Ipilimumab
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pregnancy Tests
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled